Mettler Toledo International — Financial Results
Revenue Reached $4 Billion, With Services Growing Faster Than Products
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Sales (USD) | $3.8B | $3.9B | $4.0B |
| USD Growth | — | +2% | +4% |
| Local Currency Growth | — | +3% | +3% |
| Service Revenue Growth (local currency) | — | +7% | +7% |
The company crossed $4 billion in annual sales for the first time, growing 4% in dollar terms and 3% stripping out currency moves. Notably, service revenue — repairs, calibration, compliance, and maintenance contracts — grew at 7% in local currency, outpacing product sales which grew just 1%. A faster-growing service business matters because it tends to be more predictable and carries better margins over time.
Tariffs Hit Profits Even as the Company Worked to Offset Them
| Metric | 2024 | 2025 |
|---|---|---|
| Gross Margin | 60.1% | 59.4% |
| U.S. Operations Segment Profit | $393M | $375M |
| Estimated Pre-Mitigation Tariff Cost | — | ~$50M |
New U.S. import tariffs — 15% on Swiss goods, 30% on Chinese goods, and others — cost the company roughly $50 million before any offsetting actions in 2025. This dragged gross margin (the percentage of revenue left after production costs) down from 60.1% to 59.4%, and caused U.S. segment profit to fall 5% despite revenue rising 5%. The company says it has actions in place to fully offset the current tariff levels in 2026, but warns that further tariff changes remain a real risk.
Western European Operations Were a Bright Spot; China Remains Subdued
| Segment | 2025 Profit | Change vs. 2024 |
|---|---|---|
| Western European Operations | $227M | +10% |
| Chinese Operations | $345M | ~flat |
Western Europe delivered a 10% jump in segment profit on the back of higher sales and ongoing margin expansion (efficiency) programs. China, meanwhile, has gone from $367M in profit in 2023 to roughly flat in 2025, reflecting a market that has been volatile and slow to recover. China still represents about 16% of total sales, so its trajectory matters; the company is redirecting its China focus toward pharma, food manufacturing, and chemical customers.
The Company Returns Substantial Cash to Shareholders Through Buybacks
| Year | Buyback Spend | Shares Repurchased |
|---|---|---|
| 2023 | $900M | 691,913 |
| 2024 | $850M | 645,139 |
| 2025 | $800M | 646,608 |
The company has repurchased over $10.6 billion of its own shares since 2004. In 2025, it spent $800 million buying back stock, and the board recently authorized an additional $2.75 billion for future repurchases. For 2026, management plans to spend $825–$875 million on buybacks. Share repurchases reduce the number of shares outstanding, which can increase earnings per share even when total profits are flat.
Operating Cash Flow Remains Strong and Consistent
| Year | Cash from Operations | Capital Expenditures |
|---|---|---|
| 2023 | $966M | $105M |
| 2024 | $968M | $104M |
| 2025 | $956M | $107M |
The business generates close to $1 billion in operating cash flow (cash produced by running the business, before investing or financing) every year with remarkable consistency. After spending about $107 million on equipment and systems, the company had substantial free cash flow to fund buybacks and acquisitions. Capital spending is expected to step up slightly to around $130 million in 2026.